Wolff / Fleckenstein / Philipp Drug Research and Drug Development in the 21st Century

Science and Ethics
Erscheinungsjahr 2012
ISBN: 978-3-642-74615-4
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 310 Seiten, eBook

Reihe: Bayer AG Centenary Symposium

Distinguished scientists and members of the medical
profession discuss the research and development of safe and
suitable drugs for the long-term treatment of chronic
diseases. The book provides an up-to-date survey on new
insights and technologies - as well as ethical
considerations - , since traditional means and methods of
drug research and drug development may no longer suffice to
meet the challenges of the next century.

Zielgruppe

Research

Autoren/Hrsg.

Wolff, H.P.

Fleckenstein, A.

Philipp, Egon O.

Inhaltsverzeichnis

History and Philosophy of Bayer Pharmaceutical Research.- Science, Responsibility, and Society.- Opening Remarks.- Message of Greeting.- I. Unresolved Problems of Chronic Diseases.- Demographic and Epidemiologic Trends Today.- Atherosclerosis and Coronary Heart Disease.- Rheumatoid Arthritis: A Modell of Chronic Inflammation.- Alzheimer’s Disease.- Obstructive Lung Disease.- Biological Approaches to Cancer Therapy.- Challenges and Obstacles hi Clinical Evaluations of Therapy.- Problems, Pitfalls, and Opportunities in Long-term Randomized Trials.- The Impact of Clinical Trials on Clinical Practice.- Panel Discussion I: Cost Effectiveness of Drug Development and Health Economics.- II. Advanced Technologies, Scientific Achievements.- Receptors and Messengers.- Low Density Lipoproteins and Hypercholesterolemia.- Leukotrienes in Airways and Blood Vessels.- Drug Design.- Opening Remarks.- Thoughts About Gene Regulation and Mammalian Development.- Protein Crystallography and Drug Design.- Applying Engineering Principles to the Design of Cellular Biology.- Analytical Pathophysiology and Biochemistry.- Opening Remarks.- Neurotransmitters in the Brain.- Mechanisms of Cancer Metastasis.- Panel Discussion II: Objectives of Basic Research and Predictive Value Preclinical Testing.- The Patient as a Subject to Medical Research.- Ethics of Drug Research and Drug Development.- The Functions of Ethical Committees.- Reduction of Risk to Patients Through Optimized Planning of Clinical Drug Development.- The Quality of Life of Hypertensive Patients in Long-term Studies.- Panel Discussion III: Who is Concerned with Patient Welfare in Research?.- Concluding Remarks.